|
[Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization] |
Oubiña M, Pichon-Riviere A,Gentile C Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oubiña M, Pichon-Riviere A,Gentile C Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. [Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 507. 2017 Authors' conclusions Evidence of moderate quality shows that bevacizumab, when compared with placebo, might have some effectiveness in reducing intraocular pressure in patients with neovascular glaucoma, although the information is uncertain. When compared with mitomycin c as adjuvant to trabeculectomy, no significant differences were observed in terms of intraocular pressure reduction.
Evidence of low quality shows that ranibizumab would not significantly reduce intraocular pressure when used in patients with neovascular glaucoma.
The clinical practice guidelines surveyed consider bevacizumab as an option among others including photodynamic therapy or surgery. No guidelines recommending the use of
ranibizumab were found.
The United States health sponsors consulted cover bevacizumab in patients with neovascular glaucoma. Only one of them covers ranibizumab for this indication.
As regards corneal neovascularization treatment, very low-quality evidence shows that bevacizumab might reduce the neovascularization area, however this would not necessarily mean clear clinical benefits and did not prove to be superior to other therapeutic alternatives such as photodynamic therapy. No studies comparing ranibizumab with usual treatments were found. That is why the clinical practice guidelines would not consider it as an alternative and the United States health sponsors consulted do not cover it because they consider these treatments as experimental. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Corneal Neovascularization; Glaucoma, Neovascular; Humans; Ranibizumab; Vascular Endothelial Growth Factor A Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000272 Date abstract record published 13/06/2017 |
|
|
|